Home › Mercks Investigational Once-Daily Formulation of ISENTRESS (raltegravir) Meets Primary and Secondary Endpoints in Pivotal Phase 3 Study
 

Keywords :   


Mercks Investigational Once-Daily Formulation of ISENTRESS (raltegravir) Meets Primary and Secondary Endpoints in Pivotal Phase 3 Study

2016-02-22 14:00:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. Results to be Presented at Future Medical Meeting, and Regulatory Submissions Planned for 2016 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced top-line results from the companys Phase 3 pivotal trial, ONCEMRK. ONCEMRK is evaluating an investigational once-daily formulation of ISENTRESS (raltegravir), known as raltegravir 600 mg (to be given as 2 x 600 mg once-daily), for previously untreated HIV-1 infected adults. Language: English Contact: For MerckMedia:Pamela Eisele, 267-305-3558orCarmen de Gourville, 267-305-4195orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: study primary phase secondary

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
09.05Maryland Adopts PaintCare Program
09.05Society of Cosmetic Chemists Intermountain West to Host Healthy Bite Oral Care Symposium
09.05A.Celli and Akinal Tekstil Collaborate on Line Installation
09.05Record levels of shoplifting show signs of falling
09.05National Advertising Division Recommends Amyris Clean Beauty Modify Claim
09.05RTL Luxembourg deploys Verimatrix to protect auto racing from piracy
09.05Bank of England boss weighs in on UK economy row
09.05Roku and The Trade Desk announce data-driven streaming partnership
More »